-
Mashup Score: 55
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 54
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of antineoplastic systemic therapies can result in less robust antibody titers following vaccination and possible risk of breakthrough infection. As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active immunosuppression (including chemotherapy), limited evidence is available to inform the clinical efficacy of COVID-19 vaccination across the spectrum of patients with cancer.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology https://t.co/WH5PPJySj6 #CCC19 #COVID19nCancer https://t.co/5tkdMEWUXx
-
-
Mashup Score: 1
Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of antineoplastic systemic therapies can result in less robust antibody titers following vaccination and possible risk of breakthrough infection. As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active immunosuppression (including chemotherapy), limited evidence is available to inform the clinical efficacy of COVID-19 vaccination across the spectrum of patients with cancer.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology https://t.co/WH5PPJySj6 #CCC19 #COVID19nCancer https://t.co/5tkdMEWUXx
-
-
Mashup Score: 101Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better? - 18 day(s) ago
Our assessment of cancer immunotherapies (CIT) randomized controlled trials (RCTs) published over the last two years in major journals (Appendix 2) reveals that knowledge of toxicities is still hindered by practices in the reporting and analysis of safety data.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047] - 22 day(s) ago
Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control. An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 99Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better? - 30 day(s) ago
Our assessment of cancer immunotherapies (CIT) randomized controlled trials (RCTs) published over the last two years in major journals (Appendix 2) reveals that knowledge of toxicities is still hindered by practices in the reporting and analysis of safety data.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Oncogenic extrachromosomal DNA identification using whole-genome sequencing from formalin-fixed glioblastomas - 30 day(s) ago
Glioblastoma, an area of urgent unmet clinical need, is the most common intrinsic brain cancer and frequently contains extrachromosomal DNA (ecDNA). EcDNA is increasingly recognized as a driver of cancer evolution and a mediator of therapy resistance1,2. Recent studies have implicated ecDNA as a prognostic marker across many cancer types, and a driver of glioblastoma, with emerging clinical trials aiming to leverage knowledge of ecDNA status or therapeutically target ecDNA directly3.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
🚀 Just out in @Annals_Oncology: @etop_ibcsg's position statement on antibody-drug conjugates (ADC) in lung and breast cancer. Honored to be a part of it, diving into the current evidence & future directions for clinical ADC development https://t.co/vZfXEPkLQ5 https://t.co/qBI6QPGYjB